Drug Trial Radar · NCT06061549
Modulation of SERCA2a of Intra-myocytic Calcium Trafficking in Heart Failure With Preserved Ejection Fraction
Last checked: Nov 19, 2026Latest source record: Sep 29, 2023 (this record)Source: ClinicalTrials.govMethods & limitations
Status
Recruiting
Enrollment
10
Planned (sponsor's estimate)
Start
Aug 24, 2023
Primary completion
Aug 2025
Study completion Aug 2029
Sponsor
- Lead sponsor
- Sardocor Corp.Industry
- Sponsor type
- Industry
- First posted
- Sep 29, 2023
Design
- Study type
- Interventional
- Phase
- Phase 1
- Allocation
- Not applicable (single group)
- Model
- Single group
- Masking
- None
- Primary purpose
- Treatment
- FDA-regulated drug
- Yes
- Who can join
- All sexes, from 50 years
- Healthy volunteers
- No
Summary
As written by the sponsor on the registry.
The goal of this clinical trial is to test an experimental gene therapy in participants with heart failure with preserved ejection fraction, also known as diastolic heart failure. The main questions it aims to answer are: * safety and tolerability of the gene therapy; and * whether the gene therapy helps the heart ventricles relax during filling. Participants will undergo a one-time infusion of the gene therapy in the cardiac catheterization laboratory and then be followed for safety and effects on left-sided filling pressures while exercising. The first year will have multiple in-person visits followed by 4 years of biannual phone calls.
Conditions
- Heart Failure, Diastolic
- Heart Failure With Preserved Ejection Fraction
Interventions
AAV1/SERCA2aBiological
3E13 viral genomes fixed dose
Primary outcomes
What the sponsor says the trial is designed to measure.
- Change in pulmonary capillary wedge pressure (PCWP)Time frame: Week 24 and Week 52
Locations
2 sites in 1 country. Site status is shown where the registry gives one.
Duke University
Durham, North Carolina · Recruiting
University of Texas Southwestern Medical Center
Dallas, Texas · Not yet recruiting
Contact details for sites and study staff are not shown here. To ask about taking part, use the contact information on the registry record.
For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.